Assessment of Tumor Angiogenesis Dynamic Contrast-enhanced MR Imaging and Beyond

被引:11
作者
Salem, Ahmed [1 ]
O'Connor, James P. B. [1 ]
机构
[1] Univ Manchester, Canc Res UK & EPSRC Canc Imaging Ctr, Manchester M13 9PT, Lancs, England
关键词
Angiogenesis; Biomarker; Clinical trials; DCE-MR imaging; Diagnosis; Quantitative imaging; PHASE-II TRIAL; COMBRETASTATIN A4 PHOSPHATE; BEVACIZUMAB PLUS IRINOTECAN; TYROSINE KINASE INHIBITOR; VASCULAR-TARGETING AGENT; BREAST-CANCER; PROSTATE-CANCER; RECEPTOR INHIBITOR; LIVER METASTASES; CLINICAL-TRIALS;
D O I
10.1016/j.mric.2015.08.010
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Dynamic contrast-enhanced (DCE) MR imaging is used increasingly often to evaluate tumor angiogenesis and the efficacy of antiangiogenic drugs. In clinical practice DCE-MR imaging applications are largely centered on lesion detection, characterization, and localization. In research, DCE-MR imaging helps inform decision making in early-phase clinical trials by showing efficacy and by selecting dose and schedule. However, the role of these techniques in patient selection is uncertain. Future research is required to optimize existing DCE-MR imaging methods and to fully validate these biomarkers for wider use in patient care and in drug development.
引用
收藏
页码:45 / +
页数:14
相关论文
共 99 条
[1]  
Akerley WL, 2007, J CLIN ONCOL, V25
[2]  
[Anonymous], 2018, ANTI-CANCER DRUG, DOI [DOI 10.3322/caac.20115, DOI 10.1097/CAD.0000000000000617]
[3]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[4]   A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers [J].
Baar, Joseph ;
Silverman, Paula ;
Lyons, Janice ;
Fu, Pingfu ;
Abdul-Karim, Fadi ;
Ziats, Nicholas ;
Wasman, Jay ;
Hartman, Paul ;
Jesberger, John ;
Dumadag, Leda ;
Hohler, Erin ;
Leeming, Rosemary ;
Shenk, Robert ;
Chen, Helen ;
McCrae, Keith ;
Dowlati, Afshin ;
Remick, Scot C. ;
Overmoyer, Beth .
CLINICAL CANCER RESEARCH, 2009, 15 (10) :3583-3590
[5]  
Barboriak DP, 2007, RSNA, V93, pSST09
[6]   AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].
Batchelor, Tracy T. ;
Sorensen, A. Gregory ;
di Tomaso, Emmanuelle ;
Zhang, Wei-Ting ;
Duda, Dan G. ;
Cohen, Kenneth S. ;
Kozak, Kevin R. ;
Cahill, Daniel P. ;
Chen, Poe-Jou ;
Zhu, Mingwang ;
Ancukiewicz, Marek ;
Mrugala, Maciej M. ;
Plotkin, Scott ;
Drappatz, Jan ;
Louis, David N. ;
Ivy, Percy ;
Scadden, David T. ;
Benner, Thomas ;
Loeffler, Jay S. ;
Wen, Patrick Y. ;
Jain, Rakesh K. .
CANCER CELL, 2007, 11 (01) :83-95
[7]  
Beer AJ, 2005, J NUCL MED, V46, P1333
[8]   Patterns of αvβ3 expression in primary and metastatic human breast cancer as shown by 18F-galacto-RGD PET [J].
Beer, Ambros J. ;
Niemeyer, Markus ;
Carlsen, Janette ;
Sarbia, Mario ;
Naehrig, Joerg ;
Watzlowik, Petra ;
Wester, Hans-Juergen ;
Harbeck, Nadia ;
Schwaiger, Markus .
JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (02) :255-259
[9]   Quantification of viable tumor microvascular characteristics by multispectral analysis [J].
Berry, Leanne R. ;
Barck, Kai H. ;
Go, Mary Ann ;
Ross, Jed ;
Wu, Xiumin ;
Williams, Simon P. ;
Gogineni, Alvin ;
Cole, Mary J. ;
Van Bruggen, Nicholas ;
Fuh, Germaine ;
Peale, Frank ;
Ferrara, Napoleone ;
Ross, Sarajane ;
Schwall, Ralph H. ;
Carano, Richard A. D. .
MAGNETIC RESONANCE IN MEDICINE, 2008, 60 (01) :64-72
[10]  
Bjarnason GA, 2011, J CLIN ONCOL, V29, P4627